Xenexus Pharmaceuticals is building a pipeline of small molecule therapeutics based on drug repurposing. They offer the prospect of multi-target drugs with broad applicability across a range of complex diseases. The portfolio includes the following projects.
XEN-101 is for the treatment and prevention of Alzheimer's disease.
XEN-102 is a treatment to stimulate liver regeneration.
XEN-103 is a treatment for nonalcoholic steatohepatitis.
XEN-104 is a treatment for diabetic foot ulcer.
XEN-105 is a treatment for osteoarthritic pain.
The company's strategy is to progress its drug candidates into early clinical trials and then to out license to a large pharmaceutical partner for onward development and commercialisation.